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Disordered cholesterol metabolism is linked to neurodegeneration. In this study
we investigated the profile of cholesterol metabolites found in the cerebrospinal
fluid (CSF) of Parkinson’s disease (PD) patients. When adjustments were made for
confounding variables of age and sex, 7α,(25R)26-dihydroxycholesterol and a second
oxysterol 7α,x,y-trihydroxycholest-4-en-3-one (7α,x,y-triHCO), whose exact structure is
unknown, were found to be significantly elevated in PD CSF. The likely location of the
additional hydroxy groups on the second oxysterol are on the sterol side-chain. We
found that CSF 7α-hydroxycholesterol levels correlated positively with depression in
PD patients, while two presumptively identified cholestenoic acids correlated negatively
with depression.
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INTRODUCTION
Parkinson’s disease (PD) is a chronic neurodegenerative disorder of the central nervous system
(CNS) that presents with motor deficits, but which also has many non-motor features, including
cognitive and neuropsychiatric problems. In PD, the core motor features result mainly from a
loss of dopaminergic neurons in the substantia nigra of the midbrain and their projection to the
striatum, but more widespread pathology in subcortical and cortical regions, and even outside the
CNS, underlies many of the non-motor features.
About 25% of total body cholesterol is found in the brain (Dietschy and Turley, 2004), and
dysregulated cholesterol metabolism is linked to PD as it is to a number of other neurodegenerative
conditions (Leoni et al., 2004; Leoni and Caccia, 2011; Bjorkhem et al., 2013, 2018).
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Cholesterol will not pass the blood brain barrier (BBB), and
cannot be imported from the circulation, so essentially all
brain cholesterol is synthesised in situ. Excess cholesterol is
removed from the brain by the neuron-specific cytochrome P450
(CYP) 46A1- catalyzed metabolism to 24S-hydroxycholesterol
(24S-HC, see Figure 1 for structure), which by virtue of
its side-chain hydroxy group can cross the BBB and enter
the circulation (Lutjohann et al., 1996). While 24S-HC exits
the brain, (25R)26-hydroxycholesterol (26-HC), also known by
the non-systematic name 27-hydroxycholesterol (Fakheri and
Javitt, 2012), enters the brain from the circulation (Heverin
et al., 2005), and is metabolised by CYP7B1, CYP27A1 and
hydroxysteroid dehydrogenase (HSD) 3B7 to 7α-hydroxy-3-
oxocholest-4-en-(25R)26-oic acid [7αH,3O-CA(25R), Figure 1]
which is exported from the brain to the circulation and is
also found in cerebrospinal fluid (CSF) (Meaney et al., 2007;
Ogundare et al., 2010). Plasma and CSF levels of 24S-HC have
been suggested as biomarkers for neurodegenerative disorders
(Leoni et al., 2004), and while the prevailing evidence suggests
that 24S-HC in plasma does not provide a diagnostic marker for
PD (Bjorkhem et al., 2013, 2018), some data suggests that there
may be a statistically significant elevation of 24S-HC in the CSF
of PD patients (Bjorkhem et al., 2018).
Currently, oxysterols in the circulation and in CSF are
almost exclusively analysed by mass spectrometry (MS) either
in combination with gas chromatography (GC) (i.e., GC-MS)
or with liquid chromatography (LC) (i.e., LC-MS) (Leoni et al.,
2004; Griffiths et al., 2013). Most studies of oxysterols in CSF are
not performed on the “free” non-esterified molecules which are
exported from brain but on a combination of esterified and non-
esterified molecules (Leoni et al., 2004; Bjorkhem et al., 2018).
This is for practical reasons as the non-esterified molecules make
up only a small proportion of the total as they become esterified
by lecithin–cholesterol acyltransferase (LCAT) in lipoprotein
particles within the CSF. However, there is value in analysing
the non-esterified molecules alone as these are the precise forms
exported from brain.
In the current study, we analysed “free” non-esterified
oxysterols (including cholestenoic acids) in the CSF of PD
patients and healthy controls with an aim of identifying
metabolites or pathways linked to PD. To achieve the necessary
sensitivity, we adopted a two-step derivatisation approach named
“enzyme-assisted derivatisation for sterol analysis” (EADSA) in
combination with LC-MS (Figure 2; Crick et al., 2015, 2017).
Although we did not find a statistical increase in 24S-HC in CSF
from PD patients compared to controls, we did find an increase in
7α,(25R)26-dihydroxycholesterol (7α,26-diHC), an intermediate
in the pathway from 26-HC to 7αH,3O-CA(25R) (Figure 1).
In addition, we found a positive correlation between the CSF
concentration of 7α-hydroxycholesterol (7α-HC) and scores on
the Beck Depression Inventory (BDI), which is a rating scale
commonly used to assess depression in PD. Interestingly there
were negative correlations between the presumptively identified
cholestenoic acids, 7α-hydroxy-3,24-bisoxocholest-4-en-26-oic
acid (7αH-3,24-diO-CA) and 7α,12α-dihydroxy-3-oxocholeste-
4-en-26-oic acid (7α,12α-diH,3O-CA), and scores on the BDI but
not other clinical measures. This work highlights the potential
clinical significance of the bile acid biosynthesis pathway in PD
and defines a methodology that can be used to measure the
pathway intermediates within a clinical laboratory setting.
MATERIALS AND METHODS
Subjects and Sample Collection
This work was designed in two studies: Study 1 primarily focused
on oxysterol and cholestenoic acid identification while Study 2
focused on their quantitation and relationship with a range of
PD relevant clinical measures. All patients were recruited from
the Parkinson’s Disease Research Clinic at the John van Geest
Centre for Brain Repair in Cambridge. The study was approved
by the Cambridgeshire 2 Research Ethics Committee (Ref.
08/H0308/331) and written informed consent was obtained from
all participants. Controls for Study 2 were carers of patients with
PD with no known neurological disease, or patients attending
Addenbrooke’s Hospital NHS Neurology clinics for a lumbar
puncture to investigate other symptoms (such as headache), but
with no known neurodegenerative disease.
Lumbar punctures were performed using an aseptic technique
as per standard clinical guidelines. 2–5 mL of CSF was collected.
The CSF was centrifuged at 2,000–3,000 g for 15 min and the
supernatant was stored at−80◦C prior to analysis.
Standard demographic data was collected along with
assessments of disease severity including the Movement Disorder
Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS);
neuropsychological assessments including the Addenbrooke’s
Cognitive Examination Revised (ACE-R) and semantic fluency
and assessment of depression using the BDI.
LC-MS
The LC-MS method is described in Crick et al. (2015, 2017);
it incorporated EADSA (Figure 2) to enhance sensitivity
and specificity, reversed-phase chromatography to separate
diastereoisomers, accurate mass measurement (<5 ppm)
at high-resolution (30,000 in Study 1, 120,000 in Study
2, both at m/z 400) and multistage fragmentation (MSn)
for structure determination. Quantification was performed
against added isotope-labelled standards. In Study 1
quantification was against [25,26,26,26,27,27,27-2H7]24R/S-
hydroxycholesterol ([2H7]24R/S-HC) which has been shown
to be an adequate surrogate for side-chain oxysterols and
cholestenoic acids (Crick et al., 2015). For Study 2, the additional
standard [26,26,26,27,27,27-2H6]7α,25-dihydroxycholesterol
([2H6]7α,25-diHC) was included to allow quantification of
7α,25-dihydroxycholesterol (7α,25-diHC) and 7α,26-diHC and
their 3-oxo analogues (Crick et al., 2017).
Patient Data and Statistical Analysis
Study 1
This study was designed to allow for the identification of
oxysterols including cholestenoic acids in CSF from PD patients.
CSF from 18 PD patients was analysed and compared to a
historical data set (Crick et al., 2017) of 18 control CSF samples
from people without neurodegenerative conditions. Statistical
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FIGURE 1 | Abbreviated versions of the cerebral 24-hydroxylase (left) and acidic (right) pathways of bile acid biosynthesis. Enzymes, metabolites, and reactions of
the 24-hydroxylase pathway are indicated in blue, those of the acidic pathway are in green. Enzymes/genes expressed in the brain, and metabolites observed, in
CSF are in bold. CoA intermediates are observed as the unconjugated acids in CSF. Italics indicate that the named structure is one of a number of possibilities. The
broken arrows indicate a reaction leading to elimination of C-27. Thick coloured arrows pointing upwards or downwards indicate significant positive or negative
correlations even when the confounding variables are considered. Red triangles indicate significance ignoring confounding variables, in at least one of the two
studies. The full stereochemistry and numbering system for cholesterol is indicated. Abbreviated structures are shown for other sterols ignoring ring-stereochemistry.
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FIGURE 2 | The EADSA derivatisation method. Samples are split into two equal fractions A and B. A-fractions are treated with cholesterol oxidase enzyme and
[2H5]GP, B-fractions are treated with [2H0]GP in the absence of cholesterol oxidase. LC-MS(MS3) analysis of fraction-A reveals compounds with a 3β-hydroxy-5-ene
structure plus those with a native 3-oxo-4-ene structure, while analysis of fraction-B reveals native 3-oxo-4-ene compounds only. Deconvolution of data from A and
B allows quantification of 3β-hydroxy-5-ene compounds while data in B allows quantification of native 3-oxo-4-ene compounds (and 7-oxo-5-ene).
significance was determined by the Mann-Whitney Test and
confounding variables of sex and age were not considered.
Study 2
CSF samples from a separate cohort of PD patients and controls
were analysed for oxysterols, including cholestenoic acids, and
their relationship with a range of standard clinical measures
was investigated (Table 1) in a cross-sectional study. Statistical
analysis was performed using Stata software (Stata Statistical
Software: Release 14. StataCorp LP, College Station, TX). Pairwise
correlations with oxysterol data were performed for continuous
demographic and clinical variables. Those correlations with
P < 0.05 were entered into multiple regression analyses with
the oxysterol as the dependent variable and inclusion of
relevant confounding variables. For motor scores and BDI, these
confounding variables were age, gender and years from onset of
disease. For cognitive variables BDI score was also included as
a potential confounder. For categorical variables ANOVA was
performed, again adjusting for potential confounding variables
as above. For clinical scores, data was only used if it had been
generated within1 year of the lumbar puncture.
RESULTS
Study 1—Identification of Oxysterol and
Cholestenoic Acids in CSF
Initial studies were performed on 18 CSF samples from early-
mid stage PD patients [72% male, mean (standard deviation,
SD) age = 69 (7) years, disease duration = 4 (4) years, MDS-
UPDRS motor score on treatment = 31(12), ACE-R = 89
(8), BDI = 6 (6)] with the aim of identifying non-esterified
oxysterols present in the CSF. The oxysterols identified in this
first study are listed in Table 2. In addition to the expected
monohydroxycholesterols, 24S-HC, 25-hydroxycholesterol (25-
HC) and 26-HC, we identified (but did not quantify) the
dihydroxycholesterols 7α,25-diHC and 7α,26-diHC and their
dihydroxycholest-4-en-3-ones, i.e., 7α,25-dihydroxycholest-4-
en-3-one (7α,25-diHCO) and 7α,(25R)26-dihydroxycholest-4-
en-3-one (7α,26-diHCO, Figures 1, 3). In addition, we
identified and approximately quantified the cholestenoic acids,
3β-hydroxycholest-5-en-(25R)26-oic acid (3β-HCA), and the
25R- and 25S-diastereoisomers of 3β,7β-dihydroxycholest-5-en-
26-oic (3β,7β-diHCA), of 3β,7α-dihydroxycholest-5-en-26-oic
(3β,7α-diHCA) and of 7αH,3O-CA (Figures 1, 3, 4A,B), as well
TABLE 1 | Study 2 participant demographics.
Factor (Mean ± SD) Patients (n = 37) Controls (n = 5)
Age (y) 65.10 ± 8.24 63.60 ± 8.08
Gender (% Male) 45.94 40.00
Years from disease onset 3.98 ± 5.67
MDS-UPDRS motor score (in the “ON” state) 32.82 ± 11.78
ACE-R 90.70 ± 9.46
Semantic fluency 24.8 ± 7.40
BDI 9.62 ± 7.02



















TABLE 2 | Oxysterols in CSF of PD patients and controls.
Fraction A Fraction B Sterol systematic name (common name) Abbreviation Study 1 Study 2 Note
m/z m/z ng/mL ng/mL
PD Control Significance PD Control Significance
Mean SD Mean SD PD vs Control Mean SD Mean SD PD vs Control
527.3640 522.3326 7α-Hydroxy-3-oxochol-4-en-24-oic acid 7αH,3O-14-BA 0.672 0.246 0.708 0.237 NS 0.675 0.167 0.551 0.081 NS
539.4004 534.369 7α-Hydroxy-27-nor-cholest-4-ene-3,24-dione 7αH-27-nor-C-3,24-diO 0.387 0.162 0.245 0.143 ** 0.698 0.194 0.638 0.025 NS 1
539.4368 NA Cholest-5-ene-3β,24S-diol (24S-hydroxycholesterol) 24S-HC 0.050 0.022 0.045 0.019 NS 0.015 0.009 0.008 0.004 NS
539.4368 NA Cholest-5-ene-3β,25-diol (25-hydroxycholesterol) 25-HC 0.028 0.028 0.030 0.019 NS 0.016 0.015 0.012 0.005 NS
539.4368 NA Cholest-5-ene-3β,(25R)26-diol ((25R),26-Hydroxycholesterol) 26-HC 0.113 0.064 0.100 0.028 NS 0.093 0.053 0.064 0.017 NS
539.4368 NA Cholest-5-ene-3β,7β-diol (7β-Hydroxycholesterol) 7β-HC 0.056 0.066 0.036 0.027 NS 0.181 0.474 0.082 0.034 NS 2
539.4368 534.4054 3β-Hydroxycholest-5-en-7-one (7-Oxocholesterol) 7-OC 0.601 0.513 0.378 0.225 NS 0.671 0.671 0.731 0.540 NS 2
539.4368 NA Cholest-5-ene-3β,7α-diol (7α-Hydroxycholesterol) 7α-HC 0.063 0.067 0.039 0.032 NS 0.091 0.118 0.056 0.027 NS 2
539.4368 NA Cholest-5-ene-3β,6β-diol (6β-Hydroxycholesterol) 6β-HC 0.345 0.234 0.280 0.312 NS 0.918 1.289 0.593 0.141 NS 3
537.4212 NA 9,10-Secocholesta-5,7,10-triene-3β,25-diol (25-hydroxyvitamin D3 ) 25-D3 NM NM NM NM NA 0.171 0.095 0.140 0.057 NS
551.4004 546.369 3-Oxocholesta-4,6-dien-26-oic acid – 2.654 2.426 1.546 0.468 NS 1.461 0.496 1.154 0.335 NS 4
551.4004 NA 3β-Hydroxycholesta-5,7-dien-26-oic acid – 0.318 0.334 0.079 0.099 ** 0.142 0.143 0.043 0.038 NS 5
553.4161 NA 3β,x-Dihydroxycholest-5-en-y-one 3β,x-diHC-yO NM NM NM NM NA 0.050 0.036 0.066 0.028 NS 6
553.4161 NA 3β-Hydroxycholest-5-en-(25R)26-oic acid 3β-HCA 1.073 0.793 0.959 0.416 NS 1.210 0.557 0.899 0.287 NS
555.4317 550.4003 7α,25-Dihydroxycholest-4-en-3-one 7α,25-diHCO NM NM NM NM NA 0.009 0.005 0.006 0.001 *
555.4317 NA Cholest-5-ene-3β,7α,25-triol (7α,25-Dihydroxycholesterol) 7α,25-diHC NM NM NM NM NA 0.006 0.005 0.006 0.004 NS
555.4317 550.4003 7α,(25R)26-Dihydroxycholest-4-en-3-one 7α,26-diHCO NM NM NM NM NA 0.009 0.004 0.005 0.001 **
555.4317 NA Cholest-5-ene-3β,7α,(25R)26-triol (7α,(25R)26-Dihydroxycholesterol) 7α,26-diHC NM NM NM NM NA 0.005 0.002 0.002 0.002 *
567.3953 562.3639 x-Hydroxy-3-oxocholesta-4,6-dien-26-oic acid – 0.190 0.169 0.112 0.041 NS 0.453 0.143 0.361 0.119 NS
567.3953 562.3639 x-Hydroxy-3-oxocholesta-4,6-dien-26-oic acid – 0.100 0.090 0.069 0.036 NS NM NM NM NM NA
569.4110 NA 3β,7β-Dihydroxycholest-5-en-26-oic acid 3β,7β-diHCA 0.455 0.212 0.403 0.190 NS 0.506 0.169 0.406 0.104 NS 7
569.4110 NA 3β,x,y-Trihydroxycholest-5-en-z-one 3β,x,y-triHC-zO 0.228 0.122 0.147 0.067 * 0.172 0.061 0.127 0.036 NS 8
569.4110 564.3796 7α-Hydroxy-3-oxocholest-4-en-26-oic acid 7αH,3O-CA 22.728 11.445 15.851 4.305 * 21.198 6.292 17.731 3.983 NS 7,9
569.4110 NA 3β,7α-Dihydroxycholest-5-en-26-oic acid 3β,7α-diHCA 3.235 3.308 2.042 1.577 NS 3.808 2.258 1.785 1.575 NS 7,10
571.4266 566.3952 7α,x,y-Trihydroxycholest-4-en-3-one 7α,x,y-triHCO 0.198 0.258 0.286 0.116 NS 0.116 0.062 0.068 0.013 * 11
583.3903 578.3589 7α-Hydroxy-3,24-bisoxocholest-4-en-26-oic acid 7αH,3,24-diO-CA 0.236 0.082 0.208 0.057 NS 0.285 0.094 0.227 0.065 NS 12
585.4059 580.3745 7α,24-Dihydroxy-3-oxocholest-4-en-26-oic acid 7α,24-diH,3O-CA NM NM NM NM NA 0.312 0.080 0.251 0.021 NS
585.4059 580.3745 7α,x-Dihydroxy-3-oxocholest-4-en-26-oic acid 7α,x-diH,3O-CA 5.212 1.737 2.938 0.887 *** 5.938 1.522 5.038 1.314 NS 13
585.4059 580.3745 7α,25-Dihydroxy-3-oxocholest-4-en-26-oic acid 7α,25-diH,3O-CA 1.306 0.472 0.715 0.224 *** 1.634 0.458 1.353 0.213 NS
585.4059 580.3745 7α,12α-Dihydroxy-3-oxocholest-4-en-26-oic acid 7α,12α-diH,3O-CA NM NM NM NM NA 1.100 1.176 1.157 0.600 NS
601.4008 596.3694 Trihydroxy-3-oxocholest-4-en-26-oic acid triH,3O-CA 0.021 0.063 0.077 0.041 * NM NM NM NM NA
TOTAL 7α-Hydroxy-3-oxocholest-4-en-26-oic acid 7αH,3O-CA 25.383 13.206 17.396 4.628 * 22.659 6.745 18.886 4.312 NS 14
TOTAL 3β,7α-Dihydroxycholest-5-en-26-oic acid 3β,7α-diHCA 3.553 3.477 2.121 1.648 NS 3.950 2.384 1.828 1.606 NS 15
*P < 0.05, **P < 0.01, ***P < 0.001 determined using Mann–Whitney Test. NA, not applicable.
As a visual aid concentrations are written in bold.
1. Decarboxylation product of 7α-hydroxy-3,24-bisoxocholest-4-en-26-oic acid.
2. May be formed enzymatically or by in vivo or ex vivo autoxidation.
3. 6β-HC is the dehydration product of cholestane-3β,5α,6β-triol, formed from 5,6-epoxycholesterol.
4. Dehydration product of 7αH,3O-CA.
5. Dehydration product of 3β,7-diHCA.
6. x and y probably correspond to 22 and 24 or 20 and 22, based on MS3 spectra.
7. 25R and 25S epimers measured in combination.
8. x, y and z probably 22, 25 and 24.
9. Some dehydration of 7αH,3O-CA (see 4).
10. Some dehydration of 3β,7-diHCA (see 5).
11. x any y probably 24,25, 24,26, or 25,26.
12. Undergoes decarboxylation to 7α-hydroxy-27-nor-cholest-4-ene-3,24-dione (see 1).
13. x is probably on the side-chain.
14. Total 7α-hydroxy-3-oxocholest-4-en-26-oic acid is a combination of molecule and its dehydrated analogue.
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FIGURE 3 | Abbreviated versions of the early steps in the neutral (left, in purple) and the cerebral 25-hydroxylase (right, in brown) pathways of bile acid biosynthesis.
Pathway from 7-dehydrocholesterol and cholesterol to 3β,7β-diHCA(25R) are also shown as is the path to 25-hydroxyvitamin D3 in red and black dashed boxes,
respectively. Enzymes, metabolites, and reactions of the neutral pathway are in purple, those of the 25-hydroxylase pathway are in brown, while those generating
3β,7β-diHCA(25R) are in red. Enzymes/genes expressed in brain, and metabolites observed in CSF are in bold. Italics indicate that the named structure is one of a
number of possibilities. Enzymes in italics are postulated catalysts. [O] indicates oxidation via non-enzymatic mechanism. Thick coloured arrows pointing upwards or
downwards indicate significant positive or negative correlations even when the confounding variables are considered. Red triangles indicate significance ignoring
confounding variables, in at least one of the two studies. The full stereochemistry and numbering system for cholesterol and 7-DHC is indicated. Abbreviated
structures are shown for other sterols ignoring ring-stereochemistry.
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FIGURE 4 | LC-MS(MSn) analysis of cholestenoic acids found in CSF. (A) RIC of m/z 569.4110 ± 5 ppm revealing 3β,7β-diHCA and 3β,7α-diHCA (upper panel) and
of 564.3796 ± 5 ppm revealing 7αH,3O-CA (lower panel). Each acid is present as two epimers, and each epimer gives syn and anti conformers of the GP-derivative.
(B) MS3 (M+ → M+-Py→) spectrum of 3β,7α-diHCA(25R). (C,E,G) RIC of m/z 585.4059 ± 5 ppm revealing dihydroxy-3-oxocholestenoic acids (upper panels) and
MRM-like chromatogram 585.4→ 501.3→ 427 highlighting 7α,24-diH,3O-CA (lower panel C), 585.4→ 501.3→ 455 highlighting 7α,25-diH,3O-CA (lower panel
E) and 585.4→ 501.3→ 422 highlighting 7α,12α-diH,3O-CA (lower panel G). MS3 (M+ → M+-Py→) spectra of (D) 7α,24-diH,3O-CA in CSF (upper panel) and
7α,24S-diH,3O-CA(25R) authentic standard (lower panel), (F) 7α,25-diH,3O-CA in CSF (upper panel) and 7α,25-diH,3O-CA authentic standard (lower panel), and
(H) 7α,x-diH,3O-CA (upper panel) and 7α,12α-diH,3O-CA (lower panel) in CSF.
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as uncovering a series of dihydroxy-3-oxocholest-4-enoic acids
(diH,3O-CA, Figures 4C–H). For this initial study, we did not
have access to CSF samples from controls but compared the data
from our PD patients to control data generated in a prior study
(Crick et al., 2017).
We have previously shown that the acidic pathway of
bile acid biosynthesis is at least partially active in the brain
(Ogundare et al., 2010). This pathway has two branches which
start with (25R)26-hydroxylation and (25R)26-carboxylation of
cholesterol by CYP27A1 to give 26-HC and 3β-HCA, respectively
(Figure 1). 26-HC may be derived from cholesterol in the brain
or imported from the circulation (Heverin et al., 2005). These
two metabolites are 7α-hydroxylated by CYP7B1 to give 7α,26-
diHC and 3β,7α-diHCA(25R), respectively (Figure 1) and after
oxidation at C-3 and 15 to 14 isomerisation the branches
converge at 7αH,3O-CA(25R). We observed each of these
metabolites in the CSF and notably the concentration of 7αH,3O-
CA was specifically elevated in PD CSF (P < 0.05, Table 2).
It should be noted that both 25R- and 25S-diastereoisomers
of 3β,7α-diHCA and 7αH,3O-CA are present in CSF, where
the 25R-epimer dominates, however, as the epimers are not
fully resolved chromatographically we have measured the two
in combination (Figure 4A). In the next steps of the acidic
pathway 7αH,3O-CA(25R) becomes converted to the CoA
thioester and through multiple steps to 7α,24R-dihydroxy-
3-oxocholest-4-en-(25R)26-oyl-CoA (7α,24R-diH,3O-CA(25R)-
CoA, Figure 1; Ferdinandusse et al., 2009; Autio et al., 2014;
Griffiths and Wang, 2020), and by generating the appropriate
reconstructed ion chromatogram (RIC), we were able to identify
a number of chromatographic peaks potentially corresponding
to the acid form of this structure (Figure 4C). Notably, in
CSF and plasma we do not find CoA thioesters but rather the
free acids. The CoA thioester of 7α,24R-diH,3O-CA(25R) is a
key intermediate in side-chain shortening of C27 to C24 bile
acids, becoming oxidised to 7α-hydroxy-3,24-bisoxocholest-4-
en-(25R)26-oyl-CoA (7αH,3,24-diO-CA(25R)-CoA, Figure 5F).
This metabolite is not fully stable in our methodology
partially eliminating the C-26 group to give 7α-hydroxy-
27-norcholest-4-ene-3,24-dione (7αH-27-nor-C-3,24-diO, see
Supplementary Figure 1) (Ogundare et al., 2010). We found
7αH-27-nor-C-3,24-diO to be elevated significantly in the
CSF from PD patients (P < 0.01). In combination, this
initial study suggests the acidic pathway is upregulated in the
CNS of PD patients.
We were also able to partially identify a number of other
oxysterols in the CSF based on retention time, accurate
mass and MS3 spectra, but in the absence of authentic
standards, definitive identifications were not made. These partial
identifications include 3β,x-dihydroxycholest-5-en-y-one (3β,x-
diHC-yO) where x and y may be 22 and 24, or 20 and
22, and 7α,x,y-trihydroxycholest-4-en-3-one (7α,x,y-triHCO,
Figure 5D) where x and y may be 24, 25, or 26 (italic compound
names in Figures 1, 3).
We next performed multivariate analysis on the data from
Study 1 using SIMCA software and an orthogonal projection
to latent structures discriminant analysis (OPLS-DA) and
this yielded a robust model separating PD from controls
(Supplementary Figure 2, Q2 = 0.68, ANOVA = 3.2e-7 for cross-
validated model), suggesting a cluster of cholesterol metabolites
as candidate biomarkers for PD. This data should be treated
with caution as the patient and control data were reordered at
different times and for samples collected from different hospitals
in different countries. Nevertheless, metabolites significant in
the univariate analysis (Table 2) were important in driving the
separation in the multivariate model.
Study 2—CSF Oxysterols, Disease
Status, and Clinical Measures of Disease
In this second study, data from 37 PD cases was compared
to 5 age-matched controls. Relevant demographic and clinical
variables are shown in Table 1. Internal standards were also
included allowing for the quantification of 7α,26-diHC and
7α,26-diHCO (Figure 5) of the acidic pathway and also 7α,25-
diHC and 7α,25-diHCO. The availability of samples from
matched controls collected from the same geographical area
(albeit in lower numbers than the patients) and the recording
of LC-MS data in a single study allowed us to perform a deeper
interrogation of the data than in Study 1. However, the number
of control samples was limited and therefore PD vs. control
comparisons need to be interpreted with caution.
7α,26-diHC Is Elevated in PD CSF
Following adjustment for the confounding variables of age and
sex, 7α,26-diHC and a second oxysterol 7α,x,y-triHCO whose
exact structure is unknown were found to be significantly
elevated in PD CSF (Figures 6A,B). Based on accurate mass
measurement, MS3 fragmentation and retention time 7α,x,y-
triHCO is likely to be 7α,24,25-triHCO, 7α,24,26-triHCO or
7α,25,26-triHCO (the uncertainty of structure is indicated by
italicised nomenclature in Figures 1, 3). Notably, 7α,26-diHC is
an intermediate of the acidic pathway of bile acid biosynthesis
(Figure 1). It was identified in Study 1 but not quantified due
to an absence of an appropriate internal standard. Numerically,
as in Study 1, 7αH,3O-CA (Figure 6C), 7αH-27-nor-C-3,24-diO
(and its chemically unstable precursor 7αH,3,24-diO-CA) were
elevated in PD CSF in Study 2, but not to a level of statistical
significance (Table 2).
During the intervening period between conducting Study
1 and 2, we were able to purchase the trihydroxycholestenoic
acids 3β,7α,24S-trihydroxycholest-5-en-(25R)26-oic (3β,7α,24S-
triHCA(25R)) and 3β,7α,25-trihydroxycholest-5-en-26-oic
(3β,7α,25-triHCA) acids from Avanti Polar Lipids Inc., which
are easily converted in the laboratory to 7α,24S-dihydroxy-3-
oxocholest-4-en-(25R)26-oic (7α,24S-diH,3O-CA(25R)) and
7α,25-dihydroxy-3-oxocholest-4-en-26-oic (7α,25-diH,3O-
CA) acids, respectively, by treatment with cholesterol oxidase
enzyme (Abdel-Khalik et al., 2018). This allowed us to identify
and approximately quantify both acids in the CSF from PD
patients and controls (Figures 4C–F). In the absence of 24S,25S,
24R,25R and 24R,25S diastereoisomers, it was not possible
to define the exact stereochemistry for 7α,24-diH,3O-CA,
and it may be 24S,25R, 24R,25R, 24S,25S or a mixture of all
depending on the pathway(s) of biosynthesis (Figure 1; Autio
et al., 2014). We were able to presumptively identify two other
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FIGURE 5 | LC-MS(MSn) analysis of dihydroxycholesterols, dihydroxycholestenones, trihydroxycholestenones, and hydroxybisoxocholestenoic acid in CSF. (A) RIC
of 555.4317 ± 5 ppm (upper panel) and 550.4003 ± 5 ppm (lower panel) revealing 7α,25-diHC, 7α,26-diHC, 7α,25-diHCO, and 7α,26-diHCO. MS3 (M+ →
M+-Py→) spectra revealing (B) 7α,25-diHC and (C) 7α,26-diHC. (D) RIC of 566.3952 ± 3 ppm corresponding to 7α,x,y-triHCO. (E) High resolution (100,000) mass
spectrum (upper panel) and theoretical mass spectrum (lower panel) of 7α,x,y-triHCO. (F) RIC of 578.3588 ± 3 ppm corresponding to 7αH-3,24-diO-CA. (G) High
resolution (100,000) mass spectrum (upper panel) and theoretical mass spectrum (lower panel) of 7αH,3,24-diO-CA.
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FIGURE 6 | 7α,26-diHC and 7α,x,y-triHCO are elevated in CSF from PD
patients. (A) 7α,26-diHC. (B) 7α,x,y-triHCO. (C) 7αH,3O-CA is also elevated
numerically but the significance is lost when confounding variables of age and
sex are considered. Data from Study 2.
acids, as 7α,12α-dihydroxy-3-oxocholest-4-en-(25R)26-oic acid
(7α,12α-diH,3O-CA) and 7α,x-dihydroxy-3-oxocholest-4-en-
26-oic acid (7α,x-diH,3O-CA) based on retention time, accurate
mass and MS3 spectra (Figures 4G,H). The location of the second
hydroxy group in 7α,x-diH,3O-CA is probably on the side-chain.
Combining data from Study 1 and Study 2, we have found that
the acidic pathway of bile acid biosynthesis is upregulated in the
CNS of PD patients (Figure 1).
Correlations With Clinical Data
Bivariate correlation analyses between each PD CSF oxysterol
profile and relevant demographic and clinical variables (age,
gender, disease duration, MDS-UPDRS motor score, ACE-R
score, BDI score) were performed. Correlations of significance
(at a level of P < 0.05) were found between PD CSF 24S-HC and
disease duration (r = 0.354, P = 0.032), 7α-HC and BDI (r = 0.436,
P = 0.023), 7αH-3,24-diO-CA and BDI (r = –0.527, P = 0.005)
and 7α,12α-diH,3O-CA and BDI (r = –0.418, P = 0.030).
Multivariate regression analysis with 24S-HC as the dependent
variable and age and gender as relevant covariates did not confirm
the relationship between 24S-HC and disease duration (Beta
coefficient 0.313, P = 0.060). However, multivariate analyses
did confirm the relationships between 7α-HC, 7αH-3,24-diO-
CA, 7α,12α-diH,3O-CA, and BDI, with age, gender, and disease
duration as relevant confounding covariates (7α-HC: Beta
coefficient 0.449, P = 0.031; 7αH-3,24-diO-CA: Beta coefficient
–0.510, P = 0.010; 7α,12α-diH,3O-CA: Beta coefficient –0.414,
p = 0.042, see Figure 7). There were no statistically significant
associations between any of the CSF oxysterols and motor
measures [MDS-UPDRS motor score, motor phenotype (tremor
dominant vs. postural instability subtype)] or cognitive measures
(ACE-R, semantic fluency). However, 25-hydroxyvitamin D3, the
precursor of bioactive 1α,25-dihydroxyvitamin D3, is elevated
in CSF of patients with postural instability and gait disturbance
(PIGD) compared to tremor dominant patients (TD, P = 0.04).
Although the reason for this is not known, it may be the case
that PIGD patients are more likely to be given calcium/vitamin
D supplements because they are at risk of falls. Vitamin D3
is converted to 25-hydroxyvitamin D3 in the liver and is
transported in the blood stream to the kidney where 1α,25-
dihydroxyvitamin D3 is formed.
DISCUSSION
In an early study looking at total oxysterols (where esterified
and non-esterified molecules were measured in combination)
in the CSF of PD patients and controls, concentrations of 24S-
HC and 26-HC were found to be elevated in about 10% of
PD samples above a cut off defined as the control mean + 3
standard deviations (SD) (Bjorkhem et al., 2013). However, when
considering all samples, statistically significant differences were
lost. In a follow-on study, Bjorkhem et al. (2018) found a small
(about 1.75 ng/mL cf. 1.4 ng/mL) but statistically significant
(p < 0.05) increase in 24S-HC in PD CSF. In this second study
the CSF concentration of 24S-HC was found to correlate with
disease progression. These results were suggested to relate to
the release of 24S-HC from a subtype of dying neurons in PD,
leading to an increase in 24S-HC concentration in the CSF
during disease progression (Bjorkhem et al., 2013, 2018). The
Frontiers in Aging Neuroscience | www.frontiersin.org 10 August 2021 | Volume 13 | Article 685594
fnagi-13-685594 August 24, 2021 Time: 16:59 # 11
Griffiths et al. CSF Oxysterols in PD
FIGURE 7 | (A) 7α-Hydroxycholesterol correlates positively with Beck
Depression Inventory (BDI) scores while presumptively identified acids, (B)
7α,12α-dihydroxy-3-oxochelest-4-en-26-oic, and (C)
7α-hydroxy-3,24-bisoxocholest-4-en-26-oic acids show negative correlations
with the BDI score.
explanation for the increase in the CSF content of 26-HC in a
sub-set of PD patients was suggested to be a consequence of a
defective BBB and excessive import of 26-HC from the circulation
(Bjorkhem et al., 2013, 2018).
In our current studies, we have measured the biologically
more relevant non-esterified molecules. We did not find a
statistically significant increase in 24S-HC in CSF from PD
patients in either study. 7α,26-diHC, one of the immediate down-
stream metabolites of 26-HC (Figure 1), was increased in PD
CSF following correction for age and sex (Figure 6A). Closer
evaluation of the data sets in both Study 1 and Study 2 show that
although not statistically significant when confounding variables
are adjusted for, early metabolites in the acidic pathway of bile
acid biosynthesis are elevated in the CSF from PD patients
(Figure 1). This supports the suggestion of Bjorkhem et al. (2013,
2018) that a defective BBB may be responsible for distorting
the oxysterol pattern in CSF of PD patients. An alternative
explanation is that cholesterol released by dying cells in the
PD brain is metabolised by CYP27A1, CYP7B1 and HSD3B7
and shunted into the bile acid biosynthesis pathway (Figure 1).
Interestingly, a recent study has found an upregulation of
bacteria responsible for secondary bile acid synthesis in the
gastrointestinal tract of PD patients (Li et al., 2021), although how
this may relate to CSF changes is not clear.
In brain, the origin of 26-HC may be cerebral or via import
across the BBB (Heverin et al., 2005), however, there is strong
evidence for its conversion to 7αH,3O-CA(25R) in the brain itself
(Meaney et al., 2007; Ogundare et al., 2010). Importantly, the
necessary enzymes, or their transcripts, for the conversion of
7αH,3O-CA(25R) to the C24 bile acid 7α-hydroxy-3-oxochol-4-
en-24-oic acid (7αH,3O-14-BA) are all expressed in human brain
(see Figure 1; Uhlen et al., 2015; Baloni et al., 2020).
A major route for 24S-HC metabolism is by CYP39A1
catalyzed 7α-hydroxylation to 7α,24S-dihydroxycholesterol
(7α,24S-diHC, Figure 1) in the liver and onward to bile acids
(Russell, 2003; Griffiths and Wang, 2020). CYP39A1 is, however,
also expressed in the cerebellum and at low levels in the
midbrain (Uhlen et al., 2015), providing a potential route to
bile acid biosynthesis from 24S-HC in the brain. Although we
did not identify 7α,24S-diHC in human CSF we did find the
down-stream metabolic product 7αH,3,24-diO-CA, and its
decarboxylation product 7αH-27-nor-C-3,24-diO. It should,
however, be noted that 7αH,3,24-diO-CA is also a member of
the acidic pathway (Figure 1). Interestingly, 7α,x,y-triHCO, is
elevated in the CSF of PD patients (Figure 6B), and if x and y are
24S- and 26-hydroxy groups, respectively, then this metabolite
falls into the metabolic pathway originating from 24S-HC.
Cholesterol 7α-hydroxylase (CYP7A1) is not expressed in
brain (Uhlen et al., 2015; Baloni et al., 2020), hence the presence
of 7α-HC in CSF must be via the circulation or via non-
enzymatic oxidation of cholesterol. 7α-HC represents the first
member of the neutral pathway of bile acid biosynthesis (Russell,
2003), one of the branches of this pathway proceeds through
7α,12α-diH,3O-CA which is one of the acids we presumptively
identify in CSF. CYP8B1 is the necessary sterol 12α-hydroxylase
but has not been found in human brain (Uhlen et al., 2015; Baloni
et al., 2020), suggesting that the origin of 7α,12α-diH,3O-CA
is from the circulation. While the 7α,24- and 7α,25-dihydroxy
acids found in CSF are barely detected in plasma, 7α,12α-diH,3O-
CA is present at the ng/mL level (Abdel-Khalik et al., 2017).
In combination this data argues for an extracerebral origin for
7α,12α-diH,3O-CA and its import into CSF from the circulation.
In future studies we recommend that wherever possible plasma
and CSF from the same PD patient should be analysed in parallel.
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This will support or refute the hypothesis that the origin of
some oxysterols and cholestenoic acids found in CSF is from the
circulation. Assessing the correlations for each analyte between
the two media should give a good indication if the origin of the
metabolite is extra- or intra-CNS. To investigate the possibility
of blood contamination confounding the CSF data, a simple
extension to the experimental protocol would be to record a
direct infusion mass spectrum from a few µL of CSF to identify
the presence or absence of haemoglobin. In the present study we
did not perform such an analysis, but any contamination by blood
can only be minimal as in all CSF samples 3β-HCA was only a
minor oxysterol while it is the most abundant free oxysterol in
plasma (Abdel-Khalik et al., 2017).
The levels of the oxysterols 7α-HC, 7αH-3,24-diO-CA,
7α,12α-diH,3O-CA were found to correlate with BDI score
(Figure 7) in PD cases but not with other clinical measures. No
previous studies have identified associations between oxysterols
and depression in general. As these oxysterols are predominantly
considered to originate from the circulation, this may suggest
the involvement of biological processes of systemic origin in
PD depression. Depression is known to be associated with
markers of systemic inflammation (Miller and Raison, 2016),
including in PD (Lindqvist et al., 2013), while oxysterols are
known to contribute to inflammatory processes (Duc et al.,
2019). Thus, systemic immune modulatory processes may be
a potential linking factor mediating the observed relationship
between oxysterol levels and depression. However, further studies
in larger PD and matched control cohorts will be required to
confirm and extend this association and its biological basis, as will
measurement of these metabolites in PD plasma. A caveat to the
link between oxysterols, inflammation and depression, is the lack
of correlation between the major immunoregulatory oxysterols
25-HC and 7α,25-diHC with BDI score.
Interestingly, intermediates in the acidic pathway of bile acid
biosynthesis have also been found to be elevated in people
suffering from multiple sclerosis but not in those suffering
from amyotrophic lateral sclerosis or Alzheimer’s disease (Abdel-
Khalik et al., 2017; Crick et al., 2017; Griffiths et al., 2019),
arguing against a link between a general mechanism for
neurodegeneration and cerebral bile acid biosynthesis. Never-
the-less, this work points to the potential value of measuring
bile acid precursors in CSF in the clinical chemistry laboratory.
Further studies with much greater numbers are required to assess
the potential of CSF bile acid precursors as prognostic biomarkers
or as lead compounds towards a PD therapeutic.
CONCLUSION
In conclusion, despite the limitations mentioned around
our control CSF sample collection, a number of interesting
and novel observations have been made in our study. Our
data suggests a cerebral upregulation of the acidic pathway
of bile acid biosynthesis in PD. We have also identified
a number of cholesterol metabolites whose CSF levels
correlate with depression in PD. Further studies are planned
utilising greater sample numbers to confirm or refute the
current findings.
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